Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
167 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Chronic Kidney Disease (Chronic Renal Failure) Overview 11 Therapeutics Development 12 Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview 12 Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis 13 Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies 14 Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes 17 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies 22 Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes 25 Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 26 Acceleron Pharma, Inc. 26 AFFiRiS AG 27 Angion Biomedica Corp. 28 Astellas Pharma Inc. 29 Bayer AG 30 Bio-inRen 31 Boryung Pharmaceutical Co., Ltd. 32 Celtic Biotech, Ltd. 33 Concert Pharmaceuticals, Inc. 34 Eli Lilly and Company 35 Evotec AG 36 Intercept Pharmaceuticals, Inc. 37 La Jolla Pharmaceutical Company 38 Multi Gene Vascular Systems Ltd 39 Nippon Zoki Pharmaceutical Co., Ltd. 40 OPKO Health, Inc. 41 Otsuka Holdings Co., Ltd. 42 Prolong Pharmaceuticals 43 ProMetic Life Sciences Inc. 44 Quark Pharmaceuticals, Inc. 45 Reata Pharmaceuticals, Inc. 46 Red Glead Discovery AB 47 Resverlogix Corp. 48 Sphaera Pharma Pvt. Ltd. 49 Stelic Institute & Co. 50 Toray Industries, Inc. 51 VBS Pharmaceuticals 52 Vicore Pharma AB 53 Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Target 55 Assessment by Mechanism of Action 57 Assessment by Route of Administration 59 Assessment by Molecule Type 61 Drug Profiles 63 ANG-3070 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ANG-3557 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 ANG-4011 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 AS-2444697 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ASP-6858 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 bardoxolone methyl - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 beraprost sodium SR - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 BR-05001 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 BRN-1889 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 C-21 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 calcifediol - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 CAR Peptide - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Cardiotoxin - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 CTP-499 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 CXA-10 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Drug for Kidney Diseases - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Drugs to Inhibit CYP24 for CKD and Pre-CKD - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 INT-767 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 LJPC-101 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 LY-3016859 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 LY-3113593 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 MultiGeneGraft - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 NZ-419 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 PBI-4050 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 rivaroxaban - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 RNAi Oligonucleotide for Chronic Diseases - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 RVX-208 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 Sanguinate - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 Small Molecule to Inhibit Sodium-Phosphate Cotransport for CKD and Hypertension - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 Small Molecules for Chronic Kidney Disease - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Small Molecules for Chronic Kidney Disease - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 sotatercept - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 SP-20103 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 SphK2 Program - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 SPR-494 - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 STNM-310 - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 tolvaptan - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 TRC-101 - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 Vaccine for Chronic Kidney Disease - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 Vida-5 - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 Chronic Kidney Disease (Chronic Renal Failure) - Recent Pipeline Updates 124 Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 157 Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 159 Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 160 Featured News & Press Releases 160 Apr 07, 2015: Resverlogix Receives Two Patents For RVX-208 In China 160 Mar 27, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings 160 Mar 19, 2015: Prometic Successfully Completes Its Pbi-4050 Phase Ib In Patients With Chronic Kidney Disease 160 Mar 06, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference 161 Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014 161 Oct 22, 2014: Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder 162 Aug 11, 2014: Rayaldee Phase 3 Trial Meets Primary Endpoints 162 Jul 02, 2014: Future Development Direction for Bardoxolone Methyl (RTA 402) 163 Jun 18, 2014: ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial 164 May 06, 2014: OPKO Completes Patient Enrollment in Third Phase 3 Trial of RAYALDEE 164 Appendix 166 Methodology 166 Coverage 166 Secondary Research 166 Primary Research 166 Expert Panel Validation 166 Contact Us 166 Disclaimer 167
List of Tables Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2015 12 Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Development by Companies, H1 2015 (Contd..2) 16 Number of Products under Investigation by Universities/Institutes, H1 2015 17 Comparative Analysis by Late Stage Development, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 19 Comparative Analysis by Early Stage Development, H1 2015 20 Comparative Analysis by Unknown Stage Development, H1 2015 21 Products under Development by Companies, H1 2015 22 Products under Development by Companies, H1 2015 (Contd..1) 23 Products under Development by Companies, H1 2015 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2015 25 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Acceleron Pharma, Inc., H1 2015 26 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AFFiRiS AG, H1 2015 27 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp., H1 2015 28 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc., H1 2015 29 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2015 30 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bio-inRen, H1 2015 31 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2015 32 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Celtic Biotech, Ltd., H1 2015 33 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 34 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eli Lilly and Company, H1 2015 35 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H1 2015 36 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 37 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by La Jolla Pharmaceutical Company, H1 2015 38 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 39 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H1 2015 40 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health, Inc., H1 2015 41 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 42 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals, H1 2015 43 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc., H1 2015 44 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 45 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 46 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Red Glead Discovery AB, H1 2015 47 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp., H1 2015 48 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015 49 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Stelic Institute & Co., H1 2015 50 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries, Inc., H1 2015 51 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VBS Pharmaceuticals, H1 2015 52 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H1 2015 53 Assessment by Monotherapy Products, H1 2015 54 Number of Products by Stage and Target, H1 2015 56 Number of Products by Stage and Mechanism of Action, H1 2015 58 Number of Products by Stage and Route of Administration, H1 2015 60 Number of Products by Stage and Molecule Type, H1 2015 62 Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Recent Pipeline Updates, H1 2015 124 Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2015 157 Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..1), H1 2015 158 Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2015 159
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.